Brevan Howard Capital Management LP Reduces Stock Position in Medpace Holdings, Inc. $MEDP

Brevan Howard Capital Management LP cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 41.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,241 shares of the company’s stock after selling 5,070 shares during the period. Brevan Howard Capital Management LP’s holdings in Medpace were worth $3,723,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Quent Capital LLC bought a new position in shares of Medpace in the third quarter worth $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace in the third quarter valued at $27,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Employees Retirement System of Texas bought a new stake in shares of Medpace during the 2nd quarter valued at $36,000. Finally, Root Financial Partners LLC purchased a new stake in Medpace during the 3rd quarter worth about $38,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on MEDP. Truist Financial cut their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and decreased their price target for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Royal Bank Of Canada started coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Stock Up 0.7%

Medpace stock opened at $453.64 on Tuesday. The stock has a market cap of $12.87 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.16 and a beta of 1.44. The business has a 50-day simple moving average of $520.96 and a 200 day simple moving average of $539.27. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.